Clinical Trial Update: Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of topically applied AN2690 solutions for onychomycosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• AN2690 solutions

Snippet

Sponsor: Pfizer | Conditions: Onychomycosis | Phase 2 | Status: COMPLETED